Zevenbergen Capital Investments LLC cut its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 12.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,747 shares of the biotechnology company's stock after selling 16,223 shares during the period. Zevenbergen Capital Investments LLC owned approximately 0.20% of Repligen worth $16,229,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Signaturefd LLC grew its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Resources Management Corp CT ADV acquired a new position in Repligen during the third quarter valued at approximately $37,000. Quarry LP increased its stake in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. raised its holdings in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Insider Buying and Selling at Repligen
In related news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company's stock.
Analyst Upgrades and Downgrades
RGEN has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. Finally, Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $178.64.
Get Our Latest Stock Report on RGEN
Repligen Stock Performance
Shares of Repligen stock traded down $3.71 during trading on Friday, hitting $133.41. 856,653 shares of the stock were exchanged, compared to its average volume of 673,469. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $184.98. The stock has a market capitalization of $7.49 billion, a price-to-earnings ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a fifty day moving average price of $154.21 and a 200-day moving average price of $148.14. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
